Site Map

• Welcome
  • Our Medicines
    • JULUCA
    • TRIUMEQ
      • Triumeq Prescribing Information
    • TIVICAY
      • Tivicay Prescribing Information
    • DTG+3TC
    • Two-drug, dolutegravir-based regimens 
  • Resources
    • Formulary packs
    • Videos
    • Publications

      • Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials¹

      • SWORD Studies
      • FLAMINGO study (96-week data)
      • SAILING study (48-week data)
      • SINGLE study (144-week data)
    • Posters
    • Slide Sets
    • HIV Guidelines
  • Therapy Area
    • Grants & Donations
    • ISS
  • News & Events
    • News
      • CROI 2019 - TD/TND dolutegravir▼+ lamivudine
      • CROI 2019 - Lamidol
      • CROI 2019 - Dawning sub-analysis
      • Glasgow 2018—2-drug regimen
      • Glasgow 2018—Comparable viral decay
      • Glasgow 2018 Comparison of viral replication
      • Glasgow 2018 Comparison of viral replication
      • ARIA at International AIDS Conference 2016
      • STRIIVING at International AIDS Conference 2016
      • ViiV at the 23rd Annual Conference of the British HIV Association
      • IAS 2017—NEAT022 PI/r Switch Lipid Study 48 Week data
      • IAS 2017—DAWNING interim data
      • IAS 2017—OPERA observational database
  • I am a patient
    • I am a Patient taking Juluca (dolutegravir/rilpivirine)
    • I am a patient taking Triumeq (dolutegravir/abacavir/lamivudine)
    • I am a patient taking Tivicay (dolutegravir)
    • I am a patient taking Celsentri (maraviroc)
    • I am a patient taking Kivexa (abacavir/lamivudine)
  • Contact a ViiV Healthcare Advisor
  • Report an Adverse Event
  • Privacy Policy
  • Terms and Conditions
  • Juluca